Grant RDF
pages:- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- more...
- A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional..
- A Multicenter, Randomized Double-Blind Placebo-Controlled 5-Arm, Parallel Group Trial to Assess Rotigotine Transdermal..
- A Multicenter, Randomized Double-Blind Study of the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent In...
- A Multicenter, Randomized, ....Study of 2 Mg/Kg Bolus Plus 24-Hour 0.05 Mg/Kg/Hr Infusion of Pexclizumab in Patients Un
- A Multicenter, Randomized, ...Compare the Safety and Efficacy of Intravenous Doripenem...Pneumonia (Dori-10)
- A Multicenter, Randomized, Blinded Study to Assess Safety Anand Efficacy of Pasireotide Lar Vs. Octreotide Lar..........
- A Multicenter, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic..
- A Multicenter, Randomized, D/B, Placebo-Controlled, Parellelgroup Study to Evaluate the Effect of Subcutaneous Doses 20
- A Multicenter, Randomized, Db, Plcb-Cntld, Comparative Trial of AMD3100 Versus G-Csf Plus Placebo to Mobilize and Collect
- A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone .....
- A Multicenter, Randomized, Double Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Non-Alcoholic Steatohepatitis (NASH) and fibrosis
- A Multicenter, Randomized, Double-Blind Crossover, Phase 3 Study to Determine Safety and Efficacu of Gadobutrol
- A Multicenter, Randomized, Double-Blind Placebo Controlled Study to Evaluate the Safety and Efficacy of School 530348 in a
- A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Admin.....
- A Multicenter, Randomized, Double-Blind, Parallel-Group Placebo-Controlled Variable Treatment Duration Study...
- A Multicenter, Randomized, Double-Blind, Placebo Controlled Study with Two Fixed Doses of Aripiprazole(10mg or 30mg)....
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Fixed-Dose...
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to Severely Active Crohn’s Disease who have Inadequately Responded to or are Intolerant to Immunomodulators or Anti-TNF Therapy
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel Ccr5 Antagonist, Uk427-857, in Combination
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel Ccr5 Antagonist, Uk427-857, in Combination
- A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial of Emricasan (IDN-6556), an Oral Caspase Inhibitor, in subjects with Non-Alcoholic Steatohepatitis (NASH) Fibrosis
- A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 2b Study to Compare the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2, Ribavirin) to Triple Therapy (with VX-222-Placebo) in Subjects With Genotype 1 Chronic Hepatitis C With Compensated Cirrhosis
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel Study to Eval the Efficacy and Safety of Brivaracetam
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Phase 2 Study of the Safety and Efficacy of Bms-986020....
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Phase 2B Study to Compare the Efficacy and Safety of . . .
- A Multicenter, Randomized, Double-Blinded, Dose Ranging Placebo Controlled Study Evaluation Defined Doses Of.......
- A Multicenter, Randomized, Masked, Placebo-Controlled Trial to Assess the Safety and Efficacy of Lucinactant in Acute Hy
- A Multicenter, Randomized, Masked, Placebo-Controlled Trial to Assess the Safety and Efficacy of Lucinactant in Acute Hy
- A Multicenter, Randomized, Open Label, Parallel Group, Active Control Study to Evaluate the Efficacy and Safety
- A Multicenter, Randomized, Open Label, Phase 3 Study to Compare the Safety and Efficacy of Intravenous Doripenem...